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Marine fungi represent an important but still largely unexplored source of novel and 27 
potentially bioactive secondary metabolites. The antimicrobial activity of nine sterile mycelia 28 
isolated from the green alga Flabellia petiolata collected from the Mediterranean Sea was tested on 29 
four antibiotic resistant bacterial strains using extracellular and intracellular extracts obtained from 30 
each fungal strain. The isolated fungi were identified at the molecular level and assigned to one of 31 
the Dothideomycetes, Sordariomycetes or Eurotiomycetes classes. Following assessment of the 32 
inhibition of bacterial growth (IC50), all crude extracts were subjected to preliminary 1H NMR and 33 
TLC analysis. According to the preliminary pharmacologic, spectroscopic/chromatographic results, 34 
extracts of the fungal strains MUT 4865, classified as Beauveria bassiana, and MUT 4861, 35 
classified as Microascacea sp.2, were selected for LC-HRMS analysis. Chemical profiling of 36 
antibacterial extracts from MUT 4861 and MUT 4865 by LC HRMS allowed the identification of 37 
the main components of the crude extracts. Several sphingosine bases were identified, including a 38 
compound previously unreported from natural sources, which gave a rationale to the broad 39 
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The worldwide diffusion of antibiotic-resistant microorganisms requires the development of 53 
new, efficient antimicrobial molecules. For more than half a century, the main strategy for obtaining 54 
new antimicrobial agents has consisted of semisynthetic remodeling of natural products. However, 55 
drugs obtained in this way are only temporarily effective against pathogenic microorganisms, which 56 
develop antibiotic resistance [1]. The problem regarding microbial resistance to antibiotics may be 57 
overcome by the discovery of new natural products, which, due to their chemical novelty, could 58 
inhibit unknown single or multiple microbial targets. 59 
The search for natural products of pharmaceutical interest in the marine environment has 60 
been progressing at an unprecedented rate, resulting in the discovery of a number of molecules, 61 
many of which have new carbon skeletons and interesting biological activities [2, 3]. 62 
Among marine microorganisms, fungi play a crucial role, being a reservoir of biologically 63 
active secondary metabolites [4-6]. Recently, several new metabolites from marine fungi have been 64 
reported to display notable antibacterial activities [7-9]. Despite their proven biosynthetic potential, 65 
scientific research has not intensively focused on marine fungi for seeking new drugs [10]. 66 
However, promising fungi are equipped with gene clusters potentially involved in the biosynthesis 67 
of secondary metabolites [11]. Therefore, research into the isolation, identification and 68 
characterization of new fungal strains, capable of producing useful bioactive natural compounds, 69 
should be carried out.  70 
Hence, the aim of this work was to assess the antibacterial potential of nine sterile mycelia isolated 71 
from the green alga Flabellia petiolata collected from the Mediterranean Sea, against some 72 
representative multidrug resistant (MDR) bacteria, relevant in Cystic Fibrosis and nosocomial 73 
infections, and to analyze the chemical profiles of the most active fungal crude extracts74 
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Materials and Methods 75 
Fungal strains 76 
Fungi were isolated and roughly identified from the green alga F. petiolata collected in March 77 
2010 near to Elba Island in the Mediterranean Sea [12], and are preserved at the Mycotheca 78 
Universitatis Taurinensis - MUT (DBIOS - University of Turin). All the selected fungi were 79 
revealed to be sterile mycelia and were identified by molecular analysis (Table 1). 80 
Molecular, Bioinformatics and Phylogenetic analyses 81 
Genomic DNA was extracted using Cetyl Trimethyl Ammonium Bromide (CTAB, 82 
Sigma-Aldrich St. Louis, USA) according to the protocol of Graham et al. [13]. 83 
The nrDNAInternal Transcribed Spacer (ITS) and Large ribosomal SubUnit (LSU) 84 
partial regions were amplified using the universal primers ITS1F/ITS4 (Sigma-Aldrich St. 85 
Louis, USA) and LR0R/LR7, as previously described [14]. 86 
Amplification products were sequenced at Macrogen Europe (The Netherlands). 87 
Sequences were checked and assembled using Sequencher 4.9 software and compared to 88 
those available in the GenBank database using the BLASTn option of the BLAST program 89 
(www.blast.ncbi.nlm.nih.gov) and CBS Mycobank Pairwise Sequence Alignment 90 
(www.mycobank.org). Newly generated sequences were deposited in the GenBank database 91 
and were assigned the accession numbers reported in Table 1.  92 
Phylogenetic analysis was only performed on LSU sequences, as comparable ITS 93 
sequences of fungi studied in this article are rarely found in public databases and/or poorly 94 
informative. LSU sequences were selected for phylogenetic analysis on the basis of BLASTn 95 
and CBS results. Two sequences datasets were composed, following reference [14] for 96 
Pleosporales and reference [15] for Sordariomycetes. 97 
Alignments were generated using MEGA 5.10 [16] and manually refined. 98 
Phylogenetic analyses were performed using both Bayesian Inference (BI; MrBayse3.2.2) 99 
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[17] and Maximum Likelihood (ML; RAxML v.7.3.2) [18] approaches, as previously 100 
described [14]. Bayesian Posterior Probability (BPP) values over 0.6 (with MLB over 50%) 101 
are reported in the resulting trees. 102 
 103 
Fungal growth conditions 104 
Preliminary growth condition tests were performed in order to define the most 105 
effective and appropriate medium to induce the production of bioactive secondary metabolites 106 
in the selected fungal strains. Each fungal strain was inoculated in duplicate by 10 agar plugs 107 
of 5 mm diameter cut from the edge of actively growing culture onto malt extract agar in 150 108 
ml flasks containing 100 ml of three different media: PCB (10 g of crushed potatoes and 10 g 109 
of crushed carrots in 1 L of ddH2O), MeCl (20 g malt extract, 17 g NaCl in 1 L of ddH2O) and 110 
WST30 (10 g glucose monohydrate, 5 g soya peptone, 3 g malt extract, 3 g yeast extract, 30 g 111 
NaCl). Flasks were incubated in the dark at 24°C and rotated at 150 rpm. The broth and 112 
mycelium of each strain were collected after 2 and 4 weeks and submitted to an extraction 113 
procedure for the preliminary bio-chemical analysis (see below). The MeCl medium and 4 114 
week-incubation were selected as the best conditions (24°C in the dark). Hence, each fungus 115 
was inoculated (100 agar plugs of 5 mm diameter) in 2 L flasks containing 1.5 L of MeCl, 116 
which was incubated in the dark at 24°C, at 180 rpm for 4 weeks. 117 
Extract preparation 118 
Samples were centrifuged at 11,200 x rcf for 30 min at 4 °C and filtrated in order to 119 
separate the mycelium from the culture broth. Supernatants were extracted with ethyl acetate 120 
(EtOAc) and the resulting extracts were dried-out by using a Rotavapor, weighed, solubilized 121 
in dimethyl sulfoxide (DMSO, 100%) at a final concentration of 100 mg/mL and stored at -122 
20°C. The presence of antimicrobial compounds in the mycelia was also evaluated. In order 123 
to efficiently lyse the cells, different mechanical disruption methods were used in a sequential 124 
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manner. The first step consisted of homogenization with Ultra Turrax T25 (IKA-Werke, 125 
Staufen, Germany).The homogenate was then washed twice with 20 mL of EtOAc to recover 126 
the intracellular extract; in addition, to improve the fungal lysis, mycelia were treated with 127 
liquid nitrogen (15 mL N2/g mycelium). Samples were transferred into a pre-cooled mortar 128 
and minced under liquid nitrogen with a pestle and washed twice with 20 mL of EtOAc. At 129 
the last step, to completely destroy the membrane, all the mycelium was transferred and 130 
processed in a Potter-Elvehjem homogenizer (Sigma-Aldrich, Saint Louis, MO) in the 131 
presence of EtOAc. Subsequently, the powdered mycelium was transferred into a separator 132 
funnel and mixed five times with two volumes of EtOAc. In order to increase the yield of 133 
some extracts, mycelia were further soaked in acetone for 18 hours under agitation. The 134 
whole EtOAc and acetone fractions were collected and dried-out by using a Rotavapor. Final 135 
extracts were weighed, solubilized in DMSO (100%) at a final concentration of 100 mg/mL 136 
and stored at -20°C.  137 
Antimicrobial assay 138 
The extracts produced as such were checked for the ability to inhibit the growth of a 139 
selected panel of human pathogens. An IC50 assay was used to evaluate the concentration of 140 
the extracts at which bacterial target growth was inhibited by 50%. The following multidrug 141 
resistant bacteria were used for the antimicrobial screening: Burkholderia metallica LMG 142 
24068 [19], Pseudomonas aeruginosa PA01 [20], Klebsiella pneumoniae DF12SA [21] and 143 
Staphylococcus aureus 6538P [22]. All bacteria were routinely grown at 37°C in Lysogeny 144 
broth (5 g yeast extract, 10 g sodium chloride, 10 g tryptone in 1 L of ddH2O), with the 145 
exception of S. aureus, which was grown in Mueller Hinton Broth (Applichem, Darmstadt, 146 
Germany). 147 
Extracts were placed into each well of a 96-well microtiter plate at an initial 148 
concentration of 2 mg/mL and serially 2-fold diluted using the appropriate medium. Wells 149 
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containing only DMSO (2% v/v) were used as a control to determine the effect of this solvent 150 
on bacterial growth.  151 
Cells were prepared as follows: a single colony of each pathogenic strain was used to 152 
inoculate 3 mL of liquid medium in a sterile bacteriological tube. After 5-8 h of incubation, 153 
growth was measured by monitoring the absorbance at 600 nm and about 40,000 colony-154 
forming units were dispensed into each well of the prepared plate. Plates were incubated at 155 
37°C for 20 h and growth was measured using a VICTOR X Multilabel Plate Reader 156 
(PerkinElmer, Waltham, MA) by monitoring the absorbance at 600 nm.  157 
Metabolic profiling of crude extracts 158 
All crude extracts were subjected to Thin Layer Chromatography (TLC) analysis and 159 
1H Nuclear Magnetic Resonance (NMR). TLC analysis was carried out on Alugram silica gel 160 
G/UV254 plates with solvent mixture of different polarity using vanillin reagent as revelation 161 
system; 1H NMR analysis were performed with Varian  INOVA  400  MHz instrument,  in  162 
CDCl3 solvent,  at  room temperature with tetramethylsilane (TMS) as internal reference. 163 
Selected extracts were analyzed using a LTQ XL Liquid Chromatography-High Resolution 164 
Mass Spectrometry system (LC-HRMS) (ThermoScientific) equipped with the Accelera 600 165 
Pump and Accelera Auto Sampler system. A volume of 10 µl of sample was injected at a 166 
concentration of 10 mg/mL in methanol. The mixture was separated on a Phenomenex LUNA 167 
C8 (150 X 2.1 mm, 5 µm particle size) column at a flow rate of 200 µL/min, using an 168 
acetonitrile-water gradient. Mobile phase A was 90% H2O 10% acetonitrile (ACN) 0.1% 169 
formic acid (FA) and mobile phase B was 10% H2O 90% ACN 0.1% FA; the gradient started 170 
at 10% B up to 90% B in 70 min, was kept at 90% of B for 10 min before the re-equilibration 171 
step. The mass spectrometer operated in positive electrospray ionization (ESI) mode, at 4 kV 172 
capillary voltage and 280°C. The calibration procedure was carried out using 173 
ThermoScientific positive calibration solution composed of caffeine, MRFA and Ultramark. 174 
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All spectra were acquired in the m/z range from 280 to 700 u.m.a., setting resolution at 175 
30,000; MSMS spectra were acquired in an opportune m/z range using 35 of collision energy. 176 
Thermo Scientific software Xcalibur was used to obtain molecular formulas. The Molecular 177 
Formulas (MF) deduced by High-Resolution Electrospray Ionization Mass Spectrometry 178 
(HRESIMS) were checked by available data banks [23-25] and, in the case of alternative 179 
structures, they were discriminated by MSnanalysis using the data available in the literature 180 
[26] or ex-novo analysis, and then by checking diagnostic signals in the 1H NMR spectrum of 181 
the crude extracts. 182 
Results  183 
Phylogeny and taxonomic identification of the fungal isolates  184 
The molecular and phylogenetic analysis revealed that strains MUT 4859, MUT 4860, 185 
MUT 4883, MUT 4886, and MUT 4966 belong to the order Pleosporales (Dothideomycetes 186 
class). In particular, MUT 4860 was identified as Massarina sp. and MUT 4883 as 187 
Biatriospora sp., both clustering in the Biatriosporaceae family, while MUT 4859, MUT 4886 188 
and MUT 4966 were identified at the family level (Roussoellaceae, Supplementary materials 189 
Fig. S1) [27].  190 
MUT 4861, MUT 4865, and MUT 4885 belonged to the Sordariomycetes class; 191 
specifically, MUT 4865 belonged to Beauveria bassiana, while MUT 4861 and MUT 4885 192 
clustered within the Microascaceae family (Supplementary materials Fig. S2).  193 
Finally, MUT 4979 was identified as Knufia petricola (syn. Sarcinomyces petricola, 194 
Incertae sedis, Chaetothyriales, Eurotiomycetes) by both ITS and LSU sequences (homology 195 
percentage = 99%). 196 
Antimicrobial activity 197 
In order to select the best growth medium for producing the antimicrobial compounds, 198 
preliminary extractions and antimicrobial assays were performed on small-scale cultures of 199 
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fungi grown in MeCl, PCB and WST30. These analyses demonstrated that fungi grown in 200 
MeCl exhibited the highest degree of antimicrobial activity (Supplementary materials Table 201 
S1). This medium was therefore selected for further experiments. Moreover, the antimicrobial 202 
potentials of the extracellular and intracellular extracts were compared; results revealed that 203 
the latter exhibited the highest yield and activity (Supplementary materials Table S2). 204 
Starting from these preliminary results, extracts obtained from mycelium lysates were 205 
used for the antimicrobial screening, targeting a panel of MDR human pathogens. The 206 
antimicrobial activity displayed by the different fungal strains against the four MDR bacteria 207 
is reported in Table 2 as IC50 values. The resistance of each strain to Ampicillin, 208 
Chloramphenicol, Kanamycin, Tetracycline and Trimethoprim was confirmed and IC50 values 209 
are reported in Table S3 (Supplementary materials). 210 
Extracts produced from strains MUT 4861, MUT 4865, and MUT 4979 resulted as 211 
being the most active and promising ones. In particular, MUT 4861 was able to strongly 212 
inhibit B. metallica (IC50 0.5-0.25 mg/mL) and S. aureus, and was the only one to show, by 213 
both EtOAc and acetone extracts, an inhibitory effect against P. aeruginosa. Both extracts 214 
from MUT 4865 were able to inhibit B. metallica and S. aureus (IC50 0.5-0.25) and the 215 
EtOAc extracts also showed inhibition against K. pneumoniae. No effects were observed 216 
against P. aeruginosa. The extract from MUT 4979 showed antimicrobial activity against 217 
three out of the four pathogens (IC50 1.0-0.25), with the exception of K. pneumoniae. Extracts 218 
of MUT 4859, 4860, and 4966 only showed a significant activity against B. metallica and S. 219 
aureus, which were the most sensitive bacterial strains to the fungal extracts. MUT 4883, 220 
4885 and 4886 extracts were the weakest strains showing no significant effects against the 221 
target bacteria. Acetone extracts showed similar antimicrobial activity compared to EtOAc 222 
extracts. The only exception was MUT 4861, of which the acetone extract was more active 223 
than the EtOAc extract. 224 
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Overall, the most promising strains were MUT 4865, 4979 and 4861,which exhibited 225 
the highest degree of antibacterial activity. 226 
Secondary Metabolite Analyses 227 
Based on the results of the preliminary pharmacologic, spectroscopic and 228 
chromatographic screening, the extracts of MUT 4865 and MUT4861 were selected for the 229 
chemical profiling and were analyzed by LC-HRMS. Other strains did not produce detectable 230 
amounts of secondary metabolites under cultivation conditions and, therefore, revealing their 231 
potential of secondary metabolite production will require further investigation. 232 
Beauveria bassiana MUT 4865: both acetone and EtOAc extracts were subjected to 233 
HRESIMS analysis (Fig. 1A). Compound 1 analyzed for C22H43O2N by HRMS analysis 234 
(calculated for C22H43NO2Na: 376.3192, found [M + Na]+: 376.3195). In the MS2 spectrum 235 
(Supplementary materials Fig. S3), the sequential loss of one ammonia and two neutral water 236 
molecules indicated the presence of one amino and two hydroxyl groups. The planar structure 237 
of this compound was deduced from the analysis of the MS3 spectrum, which showed a 238 
fragmentation pattern compatible with the localization of the two double bonds at the unusual 239 
positions of 6 and 17, revealing that it corresponded to the long chain sphingadienine (Fig. 2). 240 
Therefore a 1,3-dihydroxy-2-amino-6,17-docosadiene structure was tentatively proposed. 241 
Assignment of the relative configuration of the two contiguous stereogenic centers, as well as 242 
of the two double bonds would require isolation of the compound from a large-scale 243 
cultivation batch of the fungal strain. 244 
As shown in Fig. 1B, the acetone extract did not contain a detectable amount of 245 
compound 1, whereas some sphingosine compounds were detected, such as phytosphingosine 246 
(2), dihydrosphingosine (3) and phytoceramide C2 (4). The MS2 pattern analysis (Table 3 and 247 
Supplementary materials Fig. S4-S6) leads to a straightforward assignment of a planar 248 
structure to these compounds. 249 
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Compound 5, which was present in both EtOAc and acetone extracts, was tentatively 250 
identified as aphidicolin; compound 6 was tentatively identified as fusoxysporone and 251 
compound 7, a minor component of the EtOAc extract, was identified as bis (2-ethylhexyl) 252 
hexanedioic acid. 253 
Microascacea sp.2 MUT 4861: the EtOAc extract contained a very complex mixture 254 
of lipid and polysaccharide components, evidenced by 1H NMR analysis, which, however, did 255 
not allow its de-replication by HRESIMS. Conversely, the main components of the acetone 256 
extract were identified. For this fungal strain, two polar components were revealed to be 257 
sphingoid bases. 258 
In addition to phytosphingosine (2), an "unusual" sphingoid base with a molecular 259 
formula C19H39NO3 was detected. The MS2 spectrum (Supplementary materials Fig. S10) 260 
showed fragmentation peaks resulting in the sequential loss of three water molecules, whereas 261 
no ammonia elimination was measured. This finding could suggest the involvement of a 262 
nitrogen atom in an azetidine ring, as in isomeric penaresidins A and B. 263 
Although the fragmentation pattern observed in the MS3 spectrum (Supplementary 264 
materials Fig. S11) is compatible with these structures, no ambiguous information relative to 265 
the position of the hydroxyl groups, of the methyl branching, or even on the nature of 266 
unsaturation, can be drawn. 267 
Finally, Scopularide A (8) [28] was identified by MF analysis and by diagnostic MS2 268 
fragmentations (Table 4 and Supplementary materials Fig. S9). 269 
Discussion 270 
In this study, the green marine alga F. petiolata was chosen as a source of promising 271 
marine fungi since it has been previously demonstrated that fungi isolated from marine algae 272 
showed strong antimicrobial activity against several human pathogenic bacteria [29], 273 
probably deriving from the ability to protect their algal host from external threats [30]. 274 
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Identifying new fungal strains could lead to the discovery of new and unusual compounds, 275 
which can be utilized for biotechnological and pharmaceutical applications. 276 
The first step of this work was the phylogenetic affiliation of fungal strains, which was 277 
carried out according to molecular and phylogenetic analysis. Massarina sp. (MUT 4860) and 278 
Biatriospora sp. (MUT 4883) clustered in the Biatriosporaceae family, which accommodate 279 
genera that have often been collected from a range of both terrestrial and aquatic hosts, and 280 
are commonly found in decaying submerged intertidal mangrove wood [27]. Recently, it has 281 
been demonstrated that a strain identified as Biatriospora sp. is an efficient producer of 282 
secondary metabolites, in particular naphthoquinone derivatives [31]. 283 
MUT 4859, MUT 4886 and MUT 4966 clustered in the Roussoellaceae family, which 284 
includes species of saprobic fungi isolated from decaying bamboo culms or palm fronds [32]. 285 
Beauveria bassiana (MUT 4865) is a marine isolate of well-known 286 
enthomopathogenic fungus, commonly isolated from decaying arthropods or from plant tissue 287 
as an endophyte [33]. 288 
On the basis of molecular and phylogenetic data, MUT 4861 and MUT 4885 could be 289 
considered as putative new species and even new genera of the Microascales, a small order of 290 
primarily saprobic fungi in soil, rotting vegetation and dung. Some species of this order are 291 
responsible for plant diseases, while other members cause human diseases [34]. 292 
Knufia petricola (MUT 4979) is an algicolous strain of microcolonial fungus with a 293 
meristematic-black yeast morphology, which has only been previously found on stone 294 
substrates, such as unlichenized fungus with its natural ecological niche [35]. To the best of 295 
our knowledge, this is the first report of the presence of this species in a marine environment. 296 
As the antimicrobial activity of these algicolous fungi on MDR bacteria (according to 297 
the results of the bioassay tests) were in agreement with the known antimicrobial potential of 298 
marine fungi, further investigations are certainly recommended, also considering the value of 299 
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producing antimicrobial compounds from new taxonomic entities that have never been 300 
previously explored. 301 
The most promising fungal strains were MUT 4865, 4979 and 4861, which exhibited 302 
the highest degree of antibacterial activity. MUT 4865, identified as B. bassiana, 303 
representatives of which are well-known producers of insecticidals and antimicrobials [36], 304 
showed a strong activity against all the pathogens tested. For K. petricola (MUT 4979), this is 305 
the first report of an antimicrobial activity exhibited by the fungal extracts from this species. 306 
Further studies are necessary, considering that the class this organism belongs to 307 
(Eurotiomycetes) includes several species (e.g. Aspergillus spp., Paecilomyces spp., 308 
Penicillum spp.) that have been reported to be a source of many antimicrobial metabolites [37, 309 
38].  310 
Finally, MUT 4861 is of special interest due to the fact that it is presumed to belong to 311 
a new species of Microascaceae, a family that includes a number of fungi capable of 312 
producing several antimicrobial secondary metabolites [37, 38]. 313 
The chemical profiling of the most active crude extracts have highlighted the presence 314 
of chemically diverse metabolites. In particular, both strains were found to contain sphingoid 315 
bases. Diverse variants of the long chain bases sphingosine and phytosphingosine have been 316 
reported from marine organisms, especially sponges and tunicates [39, 40], but to the best of 317 
our knowledge, this is the first report of sphingosine-free bases from marine fungi. 318 
In particular, the long chain sphingadienine 2-aminodocosa-6,17-dien-1,3-diol has 319 
never been described as a free base or as a component of polar lipids from natural sources. 320 
The related docosa-4,15-sphingadienine and 4-hydroxy-docosa-15-sphingenine have been 321 
reported as components in sphingophosphonolipids from the marine gastropod Turbo 322 
cornutus [41]. Noteworthy, recent years have witnessed an ever-increasing interest towards 323 
the so-called “sphingoid bases” for their role in the regulation of physiological and 324 
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pathological conditions [42]. In particular, a recent study [43] revealed that sphingoid long-325 
chain bases displayed antibacterial activity against a broad spectrum of pathogenic bacteria, 326 
including Pseudomonas aeruginosa, Acinetobacter baumannii, Haemophilus influenzae, 327 
Moraxella catarrhalis and even Burkholderia cepacia, at nanomolar-to-low micromolar 328 
concentrations. Therefore, even though we cannot exclude, a priori, the possibility that the 329 
antimicrobial activity could rely on the combination of different molecules, compound 1, and 330 
co-occurring sphingosines 2, 3 and 4, previously reported as common components of fungal 331 
membrane sphingolipids [44], may be responsible for the antimicrobial effects exhibited by 332 
MUT 4865 crude extracts towards the pathogenic bacteria investigated so far. However, tests 333 
with the purified compound will be necessary to validate this hypothesis.  334 
Regarding the other tentatively identified components of MUT 4865 extracts, 335 
aphidilcolin is a tetracyclic diterpene with known antiviral and antimitotic properties, first 336 
isolated from the fungus Cephalosporum aphidicola [45]. Fusoxysporone, is a viscidane-type 337 
diterpene first isolated from Fusarium oxysporum [46], and is also found as a component of 338 
the cytotoxic extracts of a Penicillium strain isolated from bivalve mollusks [47]. To the best 339 
of our knowledge, no biological activities have been described for this compound, so far. 340 
Compound 7, identified as bis (2-ethylhexyl) hexanedioic acid, is known as plasticizer 341 
[48] and described as a component of cyanobacteria, Antarctic [49] and terrestrial [50] strains 342 
of Streptomyces, and of a tropical plant [51]. 343 
Sphingosine-related compounds were also detected in the EtOAc extract of 344 
Microascacea sp.2 MUT 4861, which also contains a member of the class of so-called 345 
anhydrophytosphingosines, in particular the detected compound is isomeric with azetidine-346 
derived penaresidins A and B, which were first isolated from the marine sponge Penares sp. 347 
[52].  348 
Conversely, compound 8 is a cyclodepsipeptide scopularide A, a molecule with 349 
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antiproliferative activity, previously isolated from a marine strain of the fungus 350 
Scopulariopsis brevicaulis [28], belonging to the same Microascaceae family assigned to 351 
MUT 4861. 352 
In conclusion, nine selected strains isolated from the green alga F. petiolata were 353 
chosen as a promising source of antimicrobial compounds. All fungal strains demonstrated 354 
interesting antimicrobial activity against four human pathogenic MDR bacteria. Crude 355 
extracts of three of the selected fungal strains, preserved at the MUT collection as MUT 4865, 356 
MUT 4979 and MUT 4861, were able to strongly inhibit the entire panel of pathogens. The 357 
chemical profiling of the antibacterial extracts from B. bassiana, MUT 4865, and 358 
Microascacea sp.2, MUT 4861, by LC HRMS allowed identification of the main components 359 
of the crude extracts. No detectable amounts of peptide mycotoxins, such as beauvericin or 360 
enniatins, known for their antimicrobial and anti-tumor activities [53], were detected. 361 
Isolation of several sphingosine bases, including compound 1, previously unreported from 362 
natural sources, gave a rationale to the broad spectrum of antibacterial activity exhibited by 363 
the crude extract of this fungal strain. Further experiments aimed at the isolation of pure 364 
compounds and determination of their biological activity are currently underway. 365 
 366 
Conflicts of Interest 367 
The authors declare that there are no conflicts of interest. 368 
 369 
Acknowledgments  370 
The authors are grateful to the EU KBBE Project PharmaSea 2012–2016, Grant 371 
Agreement No. 312184, the Fondazione CRT, the UIF through the PHC Galileo project 2014 372 
and the Regione Campania under POR Campania FESR 2007-2013 - O.O. 2.1 373 
(FarmaBioNet), which supported this research work. 374 
  
16 
References  375 
[1] Abad MJ, Bedoya LM, Bermejo P, Marine Compounds and their Antimicrobial Activities 376 
In: Science Against Microbial Pathogens: Communicating Current Research and 377 
Technological Advances, AM Vilas Ed, Formatex Research Centre, Badajoz, 2011. 378 
[2] Molinski T, Antifungal compounds from marine organisms. Curr Med Chem: Anti-Infect 379 
Agents 2004;3:197-220. 380 
[3] Imhoff JF, Labes A, Wiese J, Bio-mining the microbial treasures of the ocean: new natural 381 
products. Biotechnol Adv 2001;29:468-82. 382 
[4] Punyasloke B, Balsam TM, Phillip C, The current status of natural products from marine 383 
fungi and their potential as anti-infective agents. J Ind Microbiol Biotechnol 2006;33: 325-37. 384 
[5] Amira MGE, Ahmed AL, Tatsufumi O, Modulation of carcinogen metabolizing enzymes 385 
by chromanone A; a new chromone derivative from algicolous marine fungus Penicillium sp. 386 
Environ Toxicol Pharm 2009;28:317-22 387 
[6] Swathi J, Narendra K, Sowjanya KM, Satya AK, (2013) Marine fungal metabolites as a 388 
rich source of bioactive compounds. Afr J Biochem Res 2013;10: 184-196. 389 
[7] Silber J, Ohlendorf B, Labes A, Storjohann AW, Näther C, Imhoff JF, Malettinin E, an 390 
antibacterial and antifungal tropolone produced by a marine Cladosporium strain. Frontiers in 391 
Mar Sci 2014;1: 35  392 
[8] Wu B, Oesker V, Wiese W, Malien S, Schmaljohann R, Imhoff JF, Spirocyclic drimanes 393 
from the marine fungus Stachybotrys sp. strain MF347. Mar Drugs 2014;12:1924-38. 394 
  
17 
[9] Wu B, Oesker V, Wiese W, Schmaljohann R, Imhoff JF, Two new antibiotic pyridones 395 
produced by a marine fungus, Trichoderma sp. strain MF106. Mar Drugs 2014;12:1208-19. 396 
[10] Cragg GM, Newman DJ, Natural products: A continuing source of novel drug leads. 397 
Biochim Biophys Acta  2013;1830: 3670-95 398 
[11] Redou V, Navarri M, Meslet-Cladiere L, Barbier G, Burgaud G, Marine fungi from deep 399 
subseafloor sediments: species richness and adaptation. Appl Environ Microb 400 
2015;AEM04064-14. 401 
[12] Panno L, Diversity and Biotechnological potential of marine fungi associated with 402 
Mediterranean seagrasses and algae, PhD Thesis, University of Turin, Turin, 2014. 403 
[13] Graham GC, Mayers P, Henry RJ, (1994) A simplified method for the preparation of 404 
fungal genomic DNA for PCR and RAPD analysis. Biotechniques 1994;16:48-50. 405 
[14] Gnavi G, Ercole E, Panno L, Vizzini A, Varese C, Dothideomycetes and Leotiomycetes 406 
sterile mycelia isolated from the Italian seagrass Posidonia oceanica based on rDNA data. 407 
SpringerPlus 2014;3:508. 408 
[15] Tang AMC, Jeewon R, Hyde KD, Phylogenetic utility of protein (RPB2, beta-tubulin) 409 
and ribosomal (LSU, SSU) gene sequences in the systematics 410 
of Sordariomycetes (Ascomycota, Fungi). Ant Van Leeuw J Microb 2007;91:327-49. 411 
[16] Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S, MEGA 5: molecular 412 
evolutionary genetics analysis using maximum likelihood, evolutionary distance, and 413 
maximum parsimony methods Mol Biol Evol 2011:28:273-9. 414 
  
18 
[17] Huelsenbeck JP, Ronquist F, Mr Bayes: Bayesian inference of phylogeny. 415 
Bioinformatics 2001;17:754-5. 416 
[18] Stamatakis, A, RAxML - VI - HPC: maximum likelihood - based phylogenetic analyses 417 
with thousands of taxa and mixed models. Bioinformatics 2006;22:2688-90. 418 
[19] Soriano F, Huelves L, Naves P, Rodríguez-Cerrato V, del Prado G, Ruiz V, et al. In vitro 419 
activity of ciprofloxacin, moxifloxacin, vancomycin and erythromycin against planktonic and 420 
biofilm forms of Corynebacterium urealyticum. J Antimicrob Chemother  2009;17:801-9. 421 
[20] Alonso A, Campanario E, Martínez JL, Emergence of multidrug-resistant mutants is 422 
increased under antibiotic selective pressure in Pseudomonas aeruginosa. Microbiology 423 
199;145:2857-62. 424 
[21] Shahi SK, Singh VK, Kumar A, Gupta SK, Singh SK, Interaction of 425 
dihydrofolatereductase and aminoglycoside adenyltransferase enzyme from Klebsiella 426 
pneumoniae multidrug resistant strain DF12SA with clindamycin: a molecular modelling and 427 
docking study. J Mol Model 2013;19: 973-8 428 
[22] Lima DB, Torres AF, Mello CP, de Menezes RR, Sampaio TL, Canuto JA, et al. 429 
Antimicrobial effect of Dinoponera quadriceps (Hymenoptera: Formicidae) venom against 430 
Staphylococcus aureus strains. J Appl Microbiol 2014;117:390-6.  431 
[23] Blunt JW, Munro MH, Laatsch H, AntiMarin Database. University of Canterbury, 432 
Christchurch, 2006. 433 
[24] Buckingham J, Dictionary of Natural Products, Version 191, CRC Press, London, 2010. 434 
[25] SciFinder®, http://wwwcasorg/products/scifindr/indexhtml, 2015. 435 
  
19 
[26] El-Elimat T, Figueroa M, Ehrmann BM, Cech NB, Pearce CJ, Oberlies NH, High-436 
Resolution MS, MS/MS, and UV database of fungal secondary metabolites as a dereplication 437 
protocol for bioactive natural products. J. Nat Prod 2013;76:1709-16. 438 
[27] Hyde KD, Jones EBG, Liu JK, Ariyawansa H, Boehm E, Boonmee S, et al. Families of 439 
Dothideomycetes. Fungal Divers 2013;63:1-313. 440 
[28] Yu Z, Lang G, Kajahn I, Schmaljohann R, Imhoff JF, Scopularides A and B, 441 
cyclodepsipeptides from a marine sponge-derived fungus, Scopulariopsis brevicaulis. J Nat 442 
Prod 2008;71:1052-4. 443 
[29] Qiao M-F, Ji NY, Liu XH, Li K, Zhu QM, Xue QZ, Indolo diterpenes from an algicoluos 444 
isolate of Aspergillus oryzae. Bioorgan Med Chem 2010;20:5677-80. 445 
[30] Mathan S, Subramanian V, Nagamony S, Optimization and antimicrobial metabolite 446 
production from endophytic fungi Aspergillus terreus KC 582297. Eur J Exp Bio 2013;3:138-447 
44. 448 
[31] Stodůlková E, Man P, Kuzma M, Černý J, Císařová I, Kubátová A, et al. A highly 449 
diverse spectrum of naphthoquinone derivatives produced by the endophytic fungus 450 
Biatriospora sp. CCF 4378. Folia microbiol 2014;1-9. 451 
[32] Liu JK, Phookamsak R, Dai DQ, Tanaka K, Jones EBG, Xu J-C, et al. Roussoellaceae, a 452 
new pleosporalean family to accommodate the genera Neoroussoella gen nov, Roussoella and 453 
Roussoellopsis. Phytotaxa 2014;181:1-33. 454 
[33] Behie SW, Jones SJ, Bidochka MJ, Plant tissue localization of the endophytic insect 455 
pathogenic fungi Metarhizium and Beauveria. Fungal Ecol 2015;13:112-9. 456 
  
20 
[34] Zhang N, Castlebury LA, Miller AN, Huhndorf SM, Schoch CL, Seifert KA, et al. An 457 
overview of the systematics of the Sordariomycetes based on a four-gene phylogeny. 458 
Mycologia 2006;98:1076-87. 459 
[35] Wollenzien U, de Hoog GS, Krumbein W, Uijthof JM (1997) Sarcinomyces petricola, a 460 
new microcolonial fungus from marble in the Mediterranean basin. Ant Van Leeuw J Microb 461 
1997;71:281-8. 462 
[36] Sahab AF, Antimicrobial efficacy of secondary metabolites of Beauveria bassiana 463 
against selected bacteria and phytopathogenic fungi. J Appl Sci Res 2012;8:1441-4. 464 
[37] Blunt JW, Copp BR, Keyzers RA, Munro MHG, Pinsep MR, Marine natural products. 465 
Nat Prod Rep 2015;32:116-211. 466 
[38] Ebada SS, Proksch P, Marine-derived fungal metabolites, Hb25 Springer handbook of 467 
marine biotechnology, Springer Berlin Heidelberg, Berlin, 2015. 468 
[39] Molinski TF, Dalisay DS, Lievens SL, Saludes JP, Drug development from marine 469 
natural products. Nat Rev Drug Discov 2009;8:69-85. 470 
[40] Biegelmeyer R, Schröder R, Rambo DF, Dresch RR, Carraro JLF, Mothes B, et al. 471 
Sphingosines derived from marine sponge as potential multi-target drug related to disorders in 472 
cancer development. Mar. Drugs 2015;13:5552-63. 473 
[41] Hayashk A, Matsubara T, Matsuura F, Characterization of docosa-4,15-sphingadienine 474 
and 4-hydroxy-docosa-15-sphingenine in sphingophosphonolipids from Turbo cornutus by 475 
gas chromatography-mass spectrometry. Chem Phys Lipids 1975;14: 102-5. 476 
[42] Pruett ST, Bushnev A, Hagedorn K, Adiga M, Haynes CA, Sullards MC, et al. Thematic 477 
  
21 
Review Series: Sphingolipids biodiversity of sphingoid bases (“sphingosines”) and related 478 
amino alcohols. J Lipid Res 2008;49:1621-39. 479 
[43] Pewzner-Jung Y, Tavakoli Tabazavareh S, Grassmé H, Becker KA, Japtok L, Steinmann 480 
J, et al. Sphingoid long chain bases prevent lung infection by Pseudomonas aeruginosa 481 
EMBO. Mol Med 2014;6:1205-14. 482 
[44] Dickson RC, Sphingolipid functions in Saccharomyces cerevisiae: comparison to 483 
mammals Annu Rev Biochem 1998;67:27-48. 484 
[45] Bucknall RA, Moores H, Simms R, Hesp B, Antiviral effects of aphidicolin, a new 485 
antibiotic produced by Cephalosporium aphidicola. Antim Agents Chemother 1973;4:294-486 
298 487 
[46] Abraham WR, Hanssen HP, Fusoxysporone a new type of diterpene from Fusarium 488 
oxysporum. Tetrahedron 1992;48:10559-62. 489 
[47] Geiger M, Guitton Y, Vansteelandt M, Kerzaon I, Blanchet E, Robiou du Pont T, et al. 490 
Cytotoxicity and mycotoxin production of shellfish-derived Penicillium spp., a risk for 491 
shellfish consumers. Lett Appl Microbiol 2013;57:385-92.  492 
[48] Zygoura PD, Goulas AE, Riganakos KA, Kontominas MG, Migration of di-(2-493 
ethylhexyl) adipate and acetyltributyl citrate plasticizers from food-grade PVC film into 494 
isooctane: effect of gamma radiation. J Food Eng 2007;78:870-7. 495 
[49] Ivanova V, Oriol M, Montes M-J, Garcia A, Guinea J, Secondary metabolites from a 496 
Streptomyces strain isolated from Livingston Island. J Biosciences 2001;56:1-5. 497 
  
22 
[50] Elleuch L, Shaaban M, Smaoui S, Mellouli L, Karray-Rebai I, Fourati-Ben Fguira L, et 498 
al. Bioactive secondary metabolites from a new terrestrial Streptomyces sp. TN262. Appl 499 
Biochem Biotechnol 2010;162:579-93. 500 
[51] Oyugi DA, Ayorinde FO, Gugssa A, Allen A, Izevbigie EB, Eribo B, et al. Biological 501 
activity and mass spectrometric analysis of Vernonia amygdalina fractions. J Biosci Tech  502 
2011;2:287-304. 503 
[52] Kobayashi J, Cheng J, Ishibashi M, Walchli MR, Yamamura S, Ohizumi Y, Penaresidin 504 
A and B, two novel azetidine alkaloids with potent actomyosin ATPase-activating activity 505 
from the Okinawan marine sponge Penares sp. J Chem Soc 1991;1135-7. 506 
[53] Wang Q, Xu L, Beauvericin, a bioactive compound produced by fungi: a short review 507 















Legends to figures 521 
 522 
Fig. 1. ESI positive mode base peak chromatograms of the active samples MUT 4865 EtOAc 523 
extract (panel A), Acetone extract (panel B) and MUT 4861 Acetone extract (panel C). 524 
Numbers above the peaks identify the metabolites listed in Tables 2 and 3. 525 
 526 
Fig. 2. MS3 ESI positive mode spectrum of the precursor ion at m/z 359.30 derived from 527 
MSMS at m/z 376.31 and its proposed fragmentation. 528 
 529 
Fig. 3. Chemical structures of secondary metabolites (1-8) identified by LC-HRMS in the 530 





















Table 1. MUT code, taxonomic assessment of sterile mycelia isolated from F. petiolata and 550 






















number ITS and 
LSU 
4883 Biatriospora sp. 
KR014352 
KP671728 
4865 Beauveria bassiana (Bals.-Criv.) Vuill. 
KR014380 
KP671729 
4860 Massarina sp. 
KR014362 
KP671730 
4885 Microascacea sp. 1 
KR014356 
KP671717 
4861 Microascacea sp. 2 
KR014360 
KP671746 
4859 Roussoellacea sp. 1 
KR014355 
KP671716 
4886 Roussoellacea sp. 2 
KR014358 
KP671720 










Table 2. Antimicrobial activity of the fungal intracellular extracts vs four bacterial strains 569 
belonging to different species. The data are reported as capacity to inhibit the microorganisms 570 
growth in more than 50% (IC50).  Growth in the presence of 2% DMSO was considered as 571 






















B. metallica LMG 
24068    
P. aeruginosa 
PA01                    
K. Pneumoniae 
DF12SA                















4859 0.5 - 0.25  > 2.0 > 2.0 > 2.0 > 2.0 > 2.0 1.0 - 0.5  > 2.0 
4860 0.5 - 0.25 0.5 - 0.25 > 2.0 > 2.0 > 2.0 > 2.0 2.0 - 1.0 > 2.0 
4861 0.5 - 0.25 0.5 - 0.25 2.0 - 1.0 1.0 - 0.5  > 2.0 2.0 - 1.0 1.0 - 0.5 ND 
4865 0.5 - 0.25 0.5 - 0.25 > 2.0 > 2.0 1.0 - 0.5 > 2.0 0.5 - 0.25 0.5 - 0.25 
4979 1.0 - 0.5  ND 1.0 - 0.5  ND > 2.0 ND 0.5 - 0.25 ND 
4966 1.0 - 0.5 ND > 2.0 ND > 2.0 ND 1.0 - 0.5  ND 
4885 2.0 - 1.0 ND > 2.0 ND > 2.0 ND 2.0 - 1.0 ND 
4886 2.0 - 1.0 ND > 2.0 ND > 2.0 ND 2.0 - 1.0 ND 
4883 2.0 - 1.0 ND 2.0 - 1.0 ND > 2.0 ND 2.0 - 1.0 ND 
  
26 
Table 3. Annotated peaks observed in the chromatograms of the EtOAc and Acetone extracts 592 




MS and MS/MS Suggested MF Proposed structure 
23.20 376.3195 [M+Na]+ (Δppm: 
1.049) 
MS2 (Fig. S3): 359.29, 
341.28; MS3 see Fig. 2 
C22H43 NO2 2-aminodocosa-6,17-dien-1,3-diol 
(1) 
 
28.32 318.30015 (Δppm: -0.379) 
MS2 (Fig. S4) :300.29, 
282.29, 265.33  
C18H39 NO3 2-aminooctadecan-1,3,4-triol 
(4-hydroxysphiganine or 
phytosphingosine) (2) 
29.11 302.30543 (Δppm: 0.245) 
MS2 (Fig. S5): 284.29, 
266.31, 249.26 
C18H39NO2 2-aminooctadecan-1,3-diol 
 (dihydrosphingosine) (3) 
30.03 360.31079 (Δppm: -0,126) 




yl]acetamide  (phytoceramide C2) 
(4) 
45.65 339.25320 (Δppm: - 0.876) C20H34O4 Aphidicolin (5) 
54.04 287.23634 (Δppm: 0.584) 
MS2 (Fig. S7): 269.23, 
203.14, 175.11  
C20H30O Fusoxysporone (6) 
60.38 395.3309 (Δppm: 0.145) C28H42O Ergosta-5,7,22-trien-3-β-ol 
(ergosterol)  
62.89 393.3153 (Δppm: 0.401) C28H40O Ergostane derivative  
66.49 371.31453 (Δppm: -1.056)  
MS2 (Fig. S8): 259.01, 
240.70, 146.9, 128.9, 110.99  















Table 4. Annotated peaks observed in the chromatograms of the Acetone extract of 606 




MS and MSn Suggested 
MF 
Proposed structure 
31.52 318.30002 (Δppm -
0.756) 
MS2 (Fig. S4): 300.29, 
282.29, 265.33  
C18H39 NO3 2-amino-octadecane- 1,3,4- triol (4-
hydroxysphiganine or phytosphingosine) 
(2) 
34.29 330.30024 (Δppm -
0.031) 
MS2 (Fig. S10): 
312.26, 294.33, 282.32, 
256.32 
[MS3(@ 294.33)] (Fig. 
S11): 266.33, 168.18, 
154.07, 140.11, 133.01, 




MS2 (Fig. S9) 654.5, 
525.3, 507.2, 454.2, 
436.2, 323.1 
C36H57N5O7 Scopularide A (8)  
58.14 409.3101 (Δppm 0) C28H40O2 Ergostane derivative 
59.94 393.3154 (Δppm 0) C28H40O Ergostane derivative 
65.6 395.3307 (Δppm 0) 
 
C28H42O Ergosterol 
73.06 371.31576 (Δppm 0) 
MS2 (Fig. S8): 259.01, 
240.70, 146.9, 128.9, 
110.99 
 
C22H42O4 Bis(2-ethylhexyl) hexanedioic acid (7) 









Supporting Information 615 
The antimicrobial potential of algicolous marine fungi for counteracting 616 
multidrug resistant bacteria: phylogenetic diversity and chemical profiling 617 
Giorgio Gnavi, Fortunato Palma Esposito, Carmen Festa, Anna Poli, Pietro Tedesco, Renato Fani, Maria Chiara 618 
Monti, Donatella de Pascale, Maria Valeria D'Auria, Giovanna Cristina Varese 619 
 620 
Legend to Supplementary figures 621 
Fig. S1. Bayesian phylogram of Pleosporales (Dothideomycetes) taxa including the five 622 
fungal isolates (indicated as MUT) based on rDNA large subunit (LSU). Clades 623 
designation and sequences were retrieved from Gnavi et al. [14] and from GenBank. Node 624 
numbers indicate BPP over 0.60; ML bootstrap values are greater than 50%. + = strains 625 
isolated from terrestrial sources; * strains isolated from fresh water environments, mangrove 626 
swamp and salt flats; arrow indicates strains isolated from marine sources. 627 
Fig. S2. Bayesian phylogram of Sordariomycestes taxa including the three fungal 628 
isolates (indicated as MUT) based on rDNA large subunit (LSU). Clades designation and 629 
sequences were retrieved from Gnavi et al. [14] and Tang et al.[15] and from GenBank. Node 630 
numbers indicate BPP over 0.60; ML bootstrap values are greater than 50%. + = strains 631 
isolated from terrestrial sources; * strains isolated from fresh water environments, mangrove 632 
and salt flats; arrow indicates strains isolated from marine sources. 633 
Fig. S3. MS2 spectrum of compound 1.        634 
Fig. S4. MS2 spectrum of compound 2.        635 
Fig. S5. MS2 spectrum of compound 3.        636 
Fig. S6. MS2 spectrum of compound 4.        637 
Fig. S7. MS2 spectrum of compound 6.        638 
Fig. S8. MS2 spectrum of compound 7.        639 
Fig. S9. MS2 spectrum of compound 8.        640 
Fig. S10. MS2 spectrum of compound with molecular formulaC19H39NO3    641 
Fig. S11. MS3 data of compound with molecular formula C19H39NO3 on the daughter ions of 642 






Table S1. Selection of the best fungi growth media antimicrobial compounds production.  647 
Table reports the antimicrobial activity as the percentage of inhibition of a selected target 648 
bacterium (Burkholderia metallica LMG 24068) in presence of the fungal extracellular 649 
extracts from the three different growth media. MeCl medium showed the best antimicrobial 650 







































MeCl WST30 PCB 
4859 55 ± 2.4 38 ± 1.2 ND 
4860 50 ± 1.7 48 ± 2.4 ND 
4861 65 ± 3.5 38 ± 4.5 10 ± 0.6 
4865 60 ±1.0 60 ± 5.7 ND 
4883 25 ± 0.7 ND 20 ± 1.2 
4885 35 ± 1.4 33 ±3.2 25 ± 0.3 
4886 30 ± 0.4 40 ± 4.3 40 ± 0.9 
4966 50 ± 0.8 10 ± 0.2 ND 
4979 62 ± 1.4 45 ± 3.5 38 ± 0.9 
  
30 
Table S2. Comparison of the antimicrobial activity between intracellular and 687 
extracellular. extracts. Antimicrobial activity is reported as the percentage of inhibition of 688 
the selected target bacterium (Burkholderia metallica LMG 24068) in presence of 689 









































4859 70 ± 3.4 40 ± 3.2 
4860 67 ± 2.1 33 ±1.3  
4861 56 ± 0.9 30 ± 0.5 
4865 60 ± 2.5 32 ± 0.7 
4883 54 ± 3.1 25 ± 0.8 
4885 76 ± 4.3 33 ± 1.2 
4886 60 ± 3.8 10 ± 0.6 
4966 60 ± 2.1 15 ± 1.3 
4979 60 ± 6.5 30 ± 2.1 
  
31 
Table S3. Re-assessment of the antibiotic resistance of the four MDR bacterial strains 725 
belonging to different species. The data are reported as capacity to inhibit the 726 





LMG 24068                   
P. aeruginosa 
PA01                    
K. pneumoniae 
DF12SA            
S. aureus 
6538P                     
Ampicillin > 0.2 0.025 -0.012 < 0.003 < 0.003 
Chloramphenicol 0.006 - 0.003 0.006 - 0.003 < 0.003 < 0.003 
Kanamicyn 0.006 - 0.003 0.006 - 0.003 < 0.003 < 0.003 
Tetracycline 0.025 -0.012 < 0.003 0.006 - 0.003 < 0.003 


















































































































































































































































































































































































































































Phaeosphaeriaceae   
Cucurbitariaceae    
Pleosporaceae    
Leptosphaeriaceae    
Coniothyriaceae    
Didymellaceae    
Montagnulaceae
   
Lentitheciaceae  




Halojulellaceae   
Thyridariaceae   
Incertae sedis 
Roussoellaceae   
Biatriosporaceae   
Sporormiaceae    
Incertae sedis     
 Lophiostomataceae     
Melanommataceae
/Pleomassariaceae     
 Aigialaceae      
Lophiotremataceae      
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Figure S4. MS2 spectrum of compound 2 
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Figure S9. MS2 spectrum of compound 8 
 
 
Figure S10. MS2 spectrum of compound with molecular formula C19H39NO3 
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